Novartis's Entresto Voyage: Hindsight Is 20/20

 
• By Lucie Ellis-Taitt

What caused Novartis's innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto's journey and what this experience shows about the changing face of pharma's customers.

illustration drawing of lonely girl let go red shining heart on paper boat sailing in the ocean over clouds blue sky. Idea of art, freedom, let go. Graphic painting template wallpaper background
What lessons can pharma learn from Novartis's Entresto voyage in heart failure? • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas